Targeting CDK4/6 in patients with cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The cyclin D-CDK4/6-INK4-Rb pathway regulates cell cycle G1-S checkpoint.
• Dysregulation of this pathway drives cancer cell proliferation.
• This pathway is frequently altered in various cancers.

Purpose of the Study:

• To review preclinical and clinical data for selective CDK4/6 inhibitors.
• To discuss combination strategies for cancer treatment.
• To highlight the therapeutic potential of CDK4/6 inhibition.

Main Methods:

• Review of preclinical and clinical data for CDK4/6 inhibitors.
• Analysis of combination strategies with other targeted therapies.
• Examination of approved and late-stage CDK4/6 inhibitors.

Main Results:

• CDK4/6 inhibitors are promising cancer therapeutics.
• Combination therapies, including with endocrine therapy, show significant potential.
• Palbociclib, ribociclib, and abemaciclib are key agents in development.

Conclusions:

• CDK4/6 inhibitors represent a significant advancement in cancer treatment.
• Combination strategies are crucial for overcoming treatment resistance.
• Targeting the CDK4/6 pathway offers a viable therapeutic approach for various cancers.